PSY7 INDIRECT COST BURDEN OF MODERATE-TO-SEVERE PSORIASIS IN EU5 AND THE SAVINGS GENERATED BY CHOOSING GUSELKUMAB OVER ADALIMUMAB

Nov 1, 2019, 00:00
10.1016/j.jval.2019.09.2635
https://www.valueinhealthjournal.com/article/S1098-3015(19)35013-2/fulltext
Title : PSY7 INDIRECT COST BURDEN OF MODERATE-TO-SEVERE PSORIASIS IN EU5 AND THE SAVINGS GENERATED BY CHOOSING GUSELKUMAB OVER ADALIMUMAB
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)35013-2&doi=10.1016/j.jval.2019.09.2635
First page :
Section Title :
Open access? : No
Section Order : 12313
Categories :
Tags :
Regions :
ViH Article Tags :